Ipamorelin binds to the growth hormone secretagogue receptor (GHSR-1a) and stimulates the pituitary gland to release endogenous growth hormone in a pulsatile manner[1][2]. Unlike earlier growth hormone releasing peptides, ipamorelin is highly selective and does not significantly stimulate ACTH, cortisol, or prolactin release at effective doses[1][3]. After subcutaneous injection, GH levels peak within approximately 40 minutes and return to baseline by 2–3 hours[4]. This short-acting pulsatile effect makes it suitable for once-daily administration to support physiological GH patterns. Animal studies have shown that even chronic daily exposure did not significantly desensitize GH release mechanisms[5], though cycling is recommended as a precautionary measure. Ipamorelin has also demonstrated pro-motility effects in the gastrointestinal tract via GHSR-1a receptors, with preclinical and clinical studies showing it can accelerate gastric emptying[6].